Resumen de acción FAGR
Fagron NV, empresa de compuestos farmacéuticos, ofrece atención farmacéutica personalizada a hospitales, farmacias, clínicas y pacientes de todo el mundo.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Competidores de Fagron NV
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | €18.40 |
| 52 Week High | €19.06 |
| 52 Week Low | €14.64 |
| Beta | 0.27 |
| 1 Month Change | 3.60% |
| 3 Month Change | 2.05% |
| 1 Year Change | 7.92% |
| 3 Year Change | -1.08% |
| 5 Year Change | 8.04% |
| Change since IPO | 82.72% |
Noticias y actualizaciones recientes
Fagron NV's (EBR:FAGR) CEO Will Probably Find It Hard To See A Huge Raise This Year
May 07
The Returns At Fagron (EBR:FAGR) Aren't Growing
Apr 17Is Fagron (EBR:FAGR) A Risky Investment?
Mar 15Recent updates
Fagron NV's (EBR:FAGR) CEO Will Probably Find It Hard To See A Huge Raise This Year
May 07The Returns At Fagron (EBR:FAGR) Aren't Growing
Apr 17Is Fagron (EBR:FAGR) A Risky Investment?
Mar 15Earnings Tell The Story For Fagron NV (EBR:FAGR)
Feb 18Fagron (EBR:FAGR) Seems To Use Debt Quite Sensibly
Aug 11Be Wary Of Fagron (EBR:FAGR) And Its Returns On Capital
Jun 10Fagron (EBR:FAGR) Has Announced That It Will Be Increasing Its Dividend To €0.175
May 12An Intrinsic Calculation For Fagron NV (EBR:FAGR) Suggests It's 30% Undervalued
Apr 20Is Fagron (EBR:FAGR) A Risky Investment?
Apr 02Here's Why Fagron (EBR:FAGR) Can Manage Its Debt Responsibly
Oct 14Return Trends At Fagron (EBR:FAGR) Aren't Appealing
Jun 04Fagron (EBR:FAGR) Is Paying Out A Larger Dividend Than Last Year
May 13Is Fagron (EBR:FAGR) Using Too Much Debt?
Apr 13Slowing Rates Of Return At Fagron (EBR:FAGR) Leave Little Room For Excitement
Feb 16Fagron (EBR:FAGR) Has A Pretty Healthy Balance Sheet
Nov 18Fagron (EBR:FAGR) Is Experiencing Growth In Returns On Capital
Sep 25Are Investors Undervaluing Fagron NV (EBR:FAGR) By 45%?
Aug 30Fagron NV (EBR:FAGR) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 08Is Fagron (EBR:FAGR) A Risky Investment?
Jun 15Fagron NV (EBR:FAGR) Shares Could Be 49% Below Their Intrinsic Value Estimate
May 29The Returns At Fagron (EBR:FAGR) Aren't Growing
May 03Here's Why Fagron (EBR:FAGR) Can Manage Its Debt Responsibly
Mar 08Is Fagron NV (EBR:FAGR) A Smart Choice For Dividend Investors?
Feb 22The Returns At Fagron (EBR:FAGR) Provide Us With Signs Of What's To Come
Jan 31Is Fagron NV (EBR:FAGR) Popular Amongst Institutions?
Jan 14
How Much Does Fagron's (EBR:FAGR) CEO Make?
Dec 27Are Investors Undervaluing Fagron NV (EBR:FAGR) By 25%?
Dec 14Fagron (EBR:FAGR) Seems To Use Debt Quite Sensibly
Nov 30Should You Be Excited About Fagron NV's (EBR:FAGR) 26% Return On Equity?
Nov 17Is Fagron (EBR:FAGR) Using Too Much Debt?
Aug 23Why Fagron NV (EBR:FAGR) Looks Like A Quality Company
Aug 10Should Fagron (EBR:FAGR) Be Disappointed With Their 64% Profit?
Jul 28Will Fagron (EBR:FAGR) Multiply In Value Going Forward?
Jul 14What Kind Of Shareholder Owns Most Fagron NV (EBR:FAGR) Stock?
Jun 30Rentabilidad de los accionistas
| FAGR | BE Healthcare | Mercado BE | |
|---|---|---|---|
| 7D | -1.9% | 1.5% | -1.8% |
| 1Y | 7.9% | 2.4% | 5.9% |
Rentabilidad vs. Industria: FAGR superó al sector Belgian Healthcare , que obtuvo un rendimiento del -7.2% el año pasado.
Rentabilidad vs. Mercado: FAGR superó al mercado Belgian, que obtuvo un rendimiento del -2.8% el año pasado.
Volatilidad de los precios
| FAGR volatility | |
|---|---|
| FAGR Average Weekly Movement | 2.4% |
| Healthcare Industry Average Movement | 4.9% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in BE Market | 7.9% |
| 10% least volatile stocks in BE Market | 2.5% |
Precio estable de las acciones: FAGR no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de FAGR (2%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1990 | 3,282 | Rafael Padilla | www.fagron.com |
Fagron NV, una empresa de compuestos farmacéuticos, ofrece atención farmacéutica personalizada a hospitales, farmacias, clínicas y pacientes de todo el mundo. Opera en tres segmentos: Essentials, Brands y Compounding Services. La empresa también innova conceptos, vehículos y formulaciones para la preparación de compuestos farmacéuticos.
Resumen de fundamentos de Fagron NV
| Estadísticas fundamentales de FAGR | |
|---|---|
| Capitalización bursátil | €1.34b |
| Beneficios(TTM) | €70.55m |
| Ingresos (TTM) | €762.99m |
19.0x
Ratio precio-beneficio (PE)1.8x
Ratio precio-ventas (PS)¿Está FAGR sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de FAGR | |
|---|---|
| Ingresos | €762.99m |
| Coste de los ingresos | €430.38m |
| Beneficio bruto | €332.61m |
| Otros gastos | €262.07m |
| Beneficios | €70.55m |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
Aug 01, 2024
| Beneficios por acción (BPA) | 0.97 |
| Margen bruto | 43.59% |
| Margen de beneficio neto | 9.25% |
| Ratio deuda/patrimonio | 69.7% |
¿Cómo se ha desempeñado FAGR a largo plazo?
Ver rendimiento histórico y comparativa